/GLTO
GLTO Stock - Galecto, Inc.
Healthcare|BiotechnologyNASDAQ
$27.17+4.50%
+$1.17 (+4.50%) • Dec 19
83
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.64
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+25.1%upside
Target: $33.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GLTO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.90 – $27.44
TARGET (TP)$34.00
STOP LOSS$25.00
RISK/REWARD1:3.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.41
52W High$33.60
52W Low$2.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-22,260,000 | $-39,905,000 | $-61,207,000 | $-52,227,000 | $-33,637,000 |
| Net Income | $-21,439,000 | $-38,349,000 | $-61,624,000 | $-51,752,000 | $-34,837,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-18.53 | $-36.08 | $-61.04 | $-50.75 | $-35.66 |
Company Overview
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$32
Average Target
↑ 17.8% Upside
Now
$32
Low
$32
Average
$32
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | Guggenheim | Initiation | Buy | $32 |
Earnings History & Surprises
GLTOBeat Rate
81%
Last 16 quarters
Avg Surprise
-154.0%
EPS vs Estimate
Beats / Misses
13/3
Last 12 quarters
Latest EPS
$-2.36
Q4 2025
EPS Surprise History
Q1 24
+25.8%
$-5.75vs$-7.75
Q2 24
+51.2%
$-5.00vs$-10.25
Q3 24
+50.0%
$-4.00vs$-8.00
Q4 24
+8.4%
$-3.39vs$-3.70
Q1 25
-67.3%
$-5.22vs$-3.12
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 18, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | — | $-2.36 | — | — |
Q3 2025 | Aug 5, 2025 | — | $-2.60 | — | — |
Q2 2025 | May 8, 2025 | — | $-1.92 | — | — |
Q1 2025 | Mar 19, 2025 | $-3.12 | $-5.22 | -67.3% | ✗ MISS |
Q4 2024 | Nov 1, 2024 | $-3.70 | $-3.39 | +8.4% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-8.00 | $-4.00 | +50.0% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $-10.25 | $-5.00 | +51.2% | ✓ BEAT |
Q1 2024 | Mar 8, 2024 | $-7.75 | $-5.75 | +25.8% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-11.75 | $-7.50 | +36.2% | ✓ BEAT |
Q3 2023 | Jul 31, 2023 | $-15.00 | $-10.25 | +31.7% | ✓ BEAT |
Q2 2023 | Apr 28, 2023 | $-14.00 | $-12.75 | +8.9% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-14.25 | $-13.75 | +3.5% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-17.00 | $-13.50 | +20.6% | ✓ BEAT |
Q3 2022 | Jul 29, 2022 | $-17.25 | $-16.75 | +2.9% | ✓ BEAT |
Q2 2022 | Apr 29, 2022 | $-0.61 | $-16.75 | -2645.9% | ✗ MISS |
Q1 2022 | Feb 17, 2022 | $-14.00 | $-13.25 | +5.4% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-14.00 | $-12.50 | +10.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-13.50 | $-12.25 | +9.3% | ✓ BEAT |
Q2 2021 | May 4, 2021 | $-0.46 | $-0.53 | -15.2% | ✗ MISS |
Latest News
Guggenheim Maintains Buy on Galecto, Raises Price Target to $36
📈 PositiveBenzinga•Dec 8, 2025, 01:35 PM
Guggenheim Initiates Coverage On Galecto with Buy Rating, Announces Price Target of $32
📈 PositiveBenzinga•Dec 1, 2025, 12:49 PM
Galecto Shares Halted On Circuit Breaker To The Upside, Stock Now Up 10.18%
📈 PositiveBenzinga•Nov 12, 2025, 02:57 PM
Galecto Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Nov 11, 2025, 07:21 PM
Shares are trading higher after Galecto announced the completion of its acquisition of Damora Therapeutics.
📈 PositiveBenzinga•Nov 10, 2025, 04:42 PM
Market-Moving News for November 10th
➖ NeutralBenzinga•Nov 10, 2025, 12:28 PM•Also: ,
Galecto Acquires Damora Therapeutics, Pays ~$284.9M In Form Of Private Placement Of Series C Non-Voting Convertible Preferred Stock
➖ NeutralBenzinga•Nov 10, 2025, 12:04 PM
Galecto Q3 EPS $(2.36) Up From $(3.39) YoY
📈 PositiveBenzinga•Nov 6, 2025, 10:00 PM
Galecto Shares Halted On Circuit Breaker To The Upside, Stock Now Up 660.92%
📈 PositiveBenzinga•Oct 7, 2025, 02:52 PM
Galecto Shares Halted On Circuit Breaker To The Upside, Stock Now Up 705.12%
📈 PositiveBenzinga•Oct 7, 2025, 01:42 PM
Frequently Asked Questions about GLTO
What is GLTO's current stock price?
Galecto, Inc. (GLTO) is currently trading at $27.17 per share. The stock has moved +4.50% today.
What is the analyst price target for GLTO?
The average analyst price target for GLTO is $34.00, based on 1 analyst.
What sector is Galecto, Inc. in?
Galecto, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GLTO's market cap?
Galecto, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does GLTO pay dividends?
No, Galecto, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
ADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$3.60
Mkt Cap: $0.0B
PHIO
Phio Pharmaceuticals Corp.
$1.07
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.92
Mkt Cap: $0.0B
Explore stocks similar to GLTO for comparison